Sun Pharma Beats US Tariff Threat: The Big Trade-Off Behind The Deal

Sun Pharmaceutical Industries has secured a deal with the US government that could give the Indian drugmaker more time to navigate Washington’s increasingly aggressive push to lower medicine prices and shift pharmaceutical manufacturing to American soil.

The agreement, involving Most-Favoured-Nation (MFN) pricing for US state Medicaid programmes, comes as the Trump administration links access to the world’s largest pharmaceutical market with lower drug prices and greater domestic production.

For Sun Pharma, the deal offers near-term protection from potential tariffs on its innovative medicines while reinforcing its commitment to expand its US manufacturing and operating footprint.

Sun Pharma Strikes Deal With US Government

Sun Pharma entered into the agreement with the US government through its North America CEO Rick Ascroft at the White House.

Under the arrangement, Sun Pharma has committed to providing MFN pricing to state Medicaid programmes, effectively ensuring that US Medicaid buyers receive the lowest available price for its medicines globally.

Importantly, the commitment will also cover future innovative medicines launched by Sun Pharma in the US, according to the company’s regulatory filing.

In return, the US government has agreed to defer Section 232 tariffs on Sun Pharma’s innovative products for more than two years.

The agreement is significant because the US is Sun Pharma’s largest individual market, accounting for around 27% of its global revenue.

The company has also been moving beyond traditional generics into higher-margin specialty and innovative medicines, particularly in dermatology, immunology, cutaneous oncology and ophthalmology. These products account for around 22% of its sales.

The US Tariff Threat

The Sun Pharma agreement comes against a broader US effort to bring pharmaceutical manufacturing and pricing under greater domestic control.

Under the tariff framework outlined by the Trump administration, imported generic drugs are set to receive a two-year zero-tariff window from August 1, 2026.

After that period, imports could face a 100% tariff for one year, followed by a 200% tariff thereafter.

The stated objective is to encourage overseas pharmaceutical companies to establish manufacturing facilities and production capabilities in the US.

The threat is particularly significant for generic-drug manufacturers because generics typically operate on relatively thin margins.

The US market also relies heavily on generics, which account for more than 90% of prescriptions dispensed in the country.

A 100% or 200% tariff could therefore make exporting medicines from overseas facilities economically difficult for companies that do not establish a US manufacturing base.

What It Means For Sun Pharma

For Sun Pharma, the agreement provides greater visibility and breathing room as Washington reshapes pharmaceutical trade policy.

The company already has manufacturing, development and commercial operations in the US and has been expanding its Western footprint. Earlier this year, it also agreed to acquire Organon & Co. at an enterprise value of $11.75 billion.

The combination of US-based operations, the Organon acquisition and the tariff deferral could help protect Sun Pharma’s growing innovative-drug business from an immediate tariff shock.

However, the MFN commitment also means the company is accepting pricing pressure in exchange for greater policy certainty.

Other Drugmakers Face A Strategic Choice

The implications extend well beyond Sun Pharma. The White House has been pursuing individual pricing agreements with more than 20 pharmaceutical companies, while companies willing to negotiate on prices or invest in US manufacturing are being offered tariff relief or deferrals.

For other foreign drugmakers, particularly those dependent on exporting finished medicines from offshore facilities, the choices are becoming narrower.

Companies may need to build or acquire US manufacturing capacity, enter joint ventures, negotiate pricing agreements or accept the risk of substantially higher tariffs.

For generic manufacturers with limited margins, absorbing a 100% tariff could be difficult, while a potential 200% levy would make the traditional export model even harder to sustain.

The broader shift signals a fundamental change in the US pharmaceutical market: access to American patients may increasingly depend not just on what drugmakers sell, but where they manufacture it and how much they charge.